Inclusion Criteria

Inclusion:

Tumor Types: All Adults age > 18 years and < 70 years with Newly Diagnosed, Intermediate
Risk or Poor-Risk AML.

Performance Status: ECOG Performance Status 0-3, patients > 65 years of age must have ECOG
performance status < 2 prior to developing leukemic symptoms. Organ Function Low blood
cell counts (ie, platelets, RBC's, WBC's)are allowed Normal kidney and liver function
required Normal heart function required Allowed Prior Therapy: Hydroxyurea, non-cytotoxic
therapy for MDS or MPN (e.g., thalidomide or lenalidomide, interferon, cytokines,
5-azacytidine or decitabine, histone deacetylase inhibitors, low-dose cytoxan, tyrosine
kinase or dual TK/src inhibitors) will be eligible for this trial.

Exclusion Criteria:

Patients cannot have been treated previously with flavopiridol. Patients cannot be
diagnosed with core-binding factor AML's. Patients cannot have APL, >50,000blasts/uL,
Patients cannot have simultaneous treatment with other chemotherapy, radiation, or
immunotherapy.

Patient cannot have uncontrolled infection Patient cannot have active CNS leukemia, active
GVHD, or other life threatening illnesses.

The patient cannot be pregnant or nursing.